This excerpt taken from the ELN 20-F filed Mar 30, 2006.
Held for Sale Assets and Liabilities
On March 20, 2006, we completed the sale of the European rights to Prialt to Eisai, which is included in our Biopharmaceuticals segment, while retaining the product rights in the United States. In accordance with SFAS 144, we reclassified the related assets (intangible assets, inventory, and prepayments) as held for sale to present them separately on the Consolidated Balance Sheet.
Share capital at December 31, 2005 and 2004 was as follows:
The Executive Shares do not confer on the holders thereof the right to receive notice of, attend or vote at any of our meetings, or the right to be paid a dividend out of our profits, except for such dividends as the directors may from time to time determine.
The B Executive Shares confer on the holders thereof the same voting rights as the holders of Ordinary Shares. The B Executive Shares do not confer on the holders thereof the right to be paid a dividend out of our profits except for such dividends as the directors may from time to time determine.
Elan Corporation, plc
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)
At the Annual General Meeting in May 1999, we were authorized to repurchase up to 15% of the issued share capital on that date. During the remainder of the year ended December 31, 1999, we purchased 621,500 Ordinary Shares of Elan at a cost of $17.4 million and these are currently held in treasury stock. In 2000, we terminated our share repurchase program.
The components of accumulated other comprehensive income/(loss), net of $Nil taxes, were as follows (in millions):